Xizang Autonomous Region People's Hospital
Lhasa, Tibet, 850000, China
NCT Number: NCT07639931
This study aims to establish a key technical system for the diagnosis and treatment of severe acute mountain sickness based on real-world clinical data in Xizang, develop standardized diagnosis and treatment protocols and an intelligent early warning model, validate its efficacy through multicenter studies, and innovate diagnostic and therapeutic technologies. It will achieve early identification, precise diagnosis, standardized treatment, and intelligent warning of severe acute mountain sickness, comprehensively improving its prevention, control and treatment success rate.
Trial opening soon.
Get Notified18 year–75 year
All sexes
Interventional
Not applicable
Lhasa, Tibet, 850000, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Traditional treatment plus CPAP or BiPAP
Traditional treatment plus inhaled nitric oxide therapy (20-40 ppm, continuous administration for 12-24 hours)
40 patients clinically diagnosed with HAPE. Peripheral venous blood samples were collected during the acute onset stage and prior to any effective intervention.
Time frame: From date of disease onset to achievement of recovery criteria ,assessed up to 36 months
Patients are defined as recovered only when all of the following criteria are met simultaneously:
Resolution of clinical symptoms: complete relief of dyspnea (no shortness of breath at rest), disappearance of cough and expectoration, and resolution of chest tightness or chest pain.
Restoration of normal physical signs: complete disappearance of lung crackles, resolution of cyanosis, and heart rate < 100 beats per minute at rest.
Normalization of physiological parameters: blood oxygen saturation (SpO₂) ≥ 90% above 3500 m altitude (≥ 88% above 4000 m altitude) and normal arterial blood gas analysis (if performed).
Improvement on imaging studies: clear bilateral lung fields on chest X-ray, and resolution of alveolar exudation without significant effusion on chest CT.
Meeting hospital discharge criteria: stable condition for more than 48 hours, recovery of self-care ability, and no requirement for continuous oxygen therapy.
Time frame: From date of disease onset to achievement of recovery criteria ,assessed up to 36 months
Patients are defined as recovered only when all of the following criteria are met simultaneously:
Recovery of consciousness: Glasgow Coma Score (GCS) of 15, full restoration of orientation, and no signs of impaired consciousness.
Resolution of neurological symptoms: complete relief of headache, and disappearance of ataxia, nausea, vomiting, blurred vision, and other related symptoms.
Normal neurological signs: disappearance of pathological reflexes, negative meningeal irritation signs, and normal cranial nerve function.
Improvement on imaging: resolution of cerebral edema, no mass effect, and normal ventricular system on head CT or MRI.
Meeting hospital discharge criteria: stable condition for more than 72 hours, recovery of activities of daily living, and no requirement for special monitoring.
Time frame: From admission to discharge, or all-cause mortality within 30 days and 90 days after discharge.
Death is defined as all-cause mortality occurring during hospitalization, or all-cause mortality within 30 days and 90 days after discharge.
Time frame: The total duration from the first day of hospitalization to recovery and discharge, assessed up to 36 months
From the first day of admission to the day of discharge
Time frame: At discharge(assessed up to 5 days)
Clinical symptoms improved by ≥50%, manifested as significant relief of dyspnea (no shortness of breath during mild activity), marked reduction in cough and expectoration, and alleviation of chest discomfort.
Physiological indicators improved, including a decrease in heart rate by ≥20 beats per minute from baseline, an increase in blood oxygen saturation by ≥5% compared with admission, and a respiratory rate < 24 breaths per minute.
Imaging examinations showed a ≥50% reduction in pulmonary exudation on chest radiograph compared with admission, or a significant reduction in lesion extent on chest CT.
Time frame: From date of the first day admimion in the ICU until the last day in the ICU, up to 48 weeks.
From the first day of admission to the day of discharge
Time frame: From the date of the first day of mechanical ventilation until the last day of mechanical ventilation,up to 48 weeks.
Duration of mechanical ventilation, calculated in hours
Time frame: At discharge(assessed up to 5 days)
total expenses incurred during hospitalization
Time frame: At discharge(assessed up to 5 days)
Duration of oxygen therapy during hospitalization (days)
Time frame: From date of admission until the date of discharge, and within 30 days and 90 days after discharge,up to 48 weeks.
such as pulmonary embolism, pneumothorax, infection, etc
Time frame: At discharge(assessed up to 5 days)
A patient is defined as having "improved" if meeting the following core criteria:
Improved consciousness: Glasgow Coma Scale (GCS) score increased by ≥3 points from admission, partial recovery of orientation, and improved response to stimuli.
Improved neurological symptoms: ≥50% reduction in headache severity (VAS score), significant improvement in ataxia, and decreased nausea and vomiting.
Improved physiological indicators: heart rate decreased by ≥15 beats per minute from baseline, blood oxygen saturation increased by ≥5% compared with admission, and blood pressure controlled within the normal range.
Time frame: From date of admission until the date of discharge, and within 30 days and 90 days after discharge,up to 48 weeks.
such as seizures, intracranial infection, brain herniation, permanent neurological deficit
Time frame: From the first day of admission to 90 days thereafter
specifically categorized as: 0 (no symptoms),
Contact information is provided by the study sponsor or research team.
Tibet Autonomous Region People's Hospital
Other
Integration and Application Demonstration of Key Diagnosis and Treatment Technologies for Severe Acute High Altitude Disease
Acronym: SAHAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07653516
Acute Mountain Sickness, Altitude Sickness
Bern, Switzerland
View Trial DetailsNCT07585227
Altitude, Altitude Hypoxia
Brétigny-sur-Orge, France
View Trial DetailsNCT07148674
Acute Mountain Sickness (AMS), Altitude Sickness
View Trial DetailsNCT07018193
Altitude Sickness, High Altitude
View Trial Details